Thoracoscopic Talc Pleurodesis Versus Bleomycin -Tranxemic Acid Mixture Injection in Chest Tube in Malignant Pleural Effusion
NCT ID: NCT06744946
Last Updated: 2024-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
60 participants
INTERVENTIONAL
2024-09-01
2024-12-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the first arm thoracoscopic talc poudrage and the second arm Bleomycin -Tranxemic mic acid mixture
the first arm is talc insufflation through medical thoracoscopy the second arm involve bleomycin- tranxemic acid mixture injection in intercostal tube
thoracoscope
bleomycin- tranxemic acid mixture pleurodesis versus thoracoscopic talc poudrage
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
thoracoscope
bleomycin- tranxemic acid mixture pleurodesis versus thoracoscopic talc poudrage
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2\. Fit patients for the procedure selected.
Exclusion Criteria
2. Hemodynamically unstable patients.
3. Bleeding diathesis.
4. Uncontrolled cough.
5. Hypoxic index less than 300.
6. Endobronchial obstruction.
7. Pleural thickening with trapped lung.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Mohamed Sabry
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Sabry
Lecturer of chest diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
mohamed sabry eltarhony, lecturer
Role: PRINCIPAL_INVESTIGATOR
Alexandria University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chest Department -Faculty of Medicine
Alexandria, Azarita, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Study Protocol
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet . 2007 May 5;369(9572):1535-1539
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Talc Pleurodesis - Bleomycin
Identifier Type: -
Identifier Source: org_study_id